Financial Performance - The Group reported revenue of HKD 15,696,000 for the three months ended June 30, 2022, representing an increase of 12.1% compared to HKD 14,006,000 in the same period of 2021[8]. - Gross profit for the same period was HKD 7,878,000, up from HKD 7,275,000, indicating a growth of 8.3% year-on-year[8]. - The Group's net profit attributable to owners for the period was HKD 1,079,000, compared to HKD 727,000 in the previous year, reflecting a significant increase of 48.3%[8]. - Basic and diluted earnings per share increased to HKD 0.13 from HKD 0.09, marking a growth of 44.4%[8]. - The total comprehensive income for the period was HKD 1,079,000, compared to HKD 727,000 in the same period last year, showing an increase of 48.3%[8]. - The Group's cost of revenue was HKD 7,818,000, which is an increase from HKD 6,731,000, resulting in a higher cost structure[8]. - Administrative and other operating expenses rose to HKD 6,495,000 from HKD 6,179,000, indicating a year-on-year increase of 5.1%[8]. - The Group's financial costs, including losses from associates, were HKD 34,000, consistent with the previous year[8]. - The Group's other income increased significantly to HKD 280,000 from HKD 12,000, reflecting a growth of 2,233.3%[8]. Revenue Sources - The company's revenue increased approximately 12% from about HKD 14,000,000 for the three months ended June 30, 2021, to about HKD 15,700,000 for the three months ended June 30, 2022, primarily due to increased revenue from medical consumables[53]. - Revenue from medical consumables was HKD 11,970,000 for the three months ended June 30, 2022, compared to HKD 10,351,000 for the same period in 2021, representing an increase of approximately 15.6%[33]. - The company reported a total revenue of HKD 15,696,000 from various sources for the three months ended June 30, 2022, compared to HKD 14,006,000 for the same period in 2021[33]. Research and Development - Research and development expenses amounted to approximately HKD 614,000 for the three months ended June 30, 2022, compared to HKD 141,000 for the same period in 2021, reflecting a significant increase in investment in R&D[38]. - The company has established a joint venture to promote and develop autonomous mobile robotic solutions in the healthcare sector, aiming to support business growth and expand its operations[50]. - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[50]. Tax and Dividends - The company incurred a tax expense of HKD 220,000 for the three months ended June 30, 2022, compared to HKD 150,000 for the same period in 2021, representing an increase of approximately 46.7%[42]. - The company did not declare any dividends for the three months ended June 30, 2022, consistent with the previous year[43]. - The board resolved not to declare any dividend for the three months ended June 30, 2022[59]. Market Outlook - The company continues to maintain a positive outlook on the healthcare industry, driven by an aging population and increasing health awareness among Hong Kong citizens[50]. Employee and Governance - The group’s employee costs increased due to the expansion of the workforce during the three months ended June 30, 2022[55]. - The company adopted a share option scheme on March 1, 2018, to incentivize selected participants for their contributions to the group[70]. - As of June 30, 2022, no share options were granted, exercised, forfeited, cancelled, or lapsed during the period[73]. - All directors confirmed compliance with the trading standards and relevant codes of conduct during the three months ended June 30, 2022[77]. - There were no conflicts of interest reported among directors or their associates in businesses that compete or may compete with the group as of June 30, 2022[79]. - The company has adopted the new corporate governance code effective January 1, 2022, and has complied with all provisions except for specific deviations[82]. - The roles of the chairman and CEO are held by the same individual, which the board believes does not compromise its independence or effectiveness[83]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, reviewed the unaudited consolidated financial statements for the three months ended June 30, 2022[85].
君百延集团(08372) - 2023 Q1 - 季度财报